Lv6
1780 积分 2023-12-20 加入
Hidradenitis suppurativa: TLSs take the center stage
9天前
已完结
Fibrosis: cross-organ biology and pathways to development of innovative drugs
9天前
已完结
GPCR drug discovery: new agents, targets and indications
9天前
已完结
Skin immune-mesenchymal interplay within tertiarylymphoid structures promotes autoimmunepathogenesis in hidradenitis suppurativa
12天前
已完结
Exploring novel drug targets for atopic dermatitis through plasma proteome with genome
18天前
已完结
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis
1个月前
已完结
Unlocking the broad health benefits and risks of GLP-1 receptor agonist drugs
1个月前
已完结
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
1个月前
已完结
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study
2个月前
已完结
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
2个月前
已完结
皖公网安备34019202002308
